Redefining the discovery and development of best-in-class oligonucleotide therapeutics
Our Mission
With OligoCreator®, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.
Global partner of choice for oligonucleotide drug discovery and development programs.
About us
We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator® platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
Mode of Action
Latest News & Events
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
- Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-
oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
Martinsried (Munich), Germany, and Zurich, Switzerland, August 24, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals to present new preclinical and translational data on SECN-15 at ASCO 2026
- SECN-15, a potential first-in-class antisense oligonucleotide (ASO), constitutes promising new treatment option for solid tumors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting with the potential to overcome resistance to checkpoint inhibitors
Martinsried (Munich), Germany, May 27, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics will present new preclinical and translational data for its proprietary lead program SECN-15, an antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago, IL, USA, on Saturday, May 30, 2026.
Secarna Pharmaceuticals presents promising additional preclinical and translational data on proprietary antisense oligonucleotide SECN-15 at AACR Annual Meeting 2026
- SECN-15 constitutes promising new therapeutic option by enhancing anti-tumor immunity and overcoming resistance to checkpoint inhibitors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting
- New findings underline reprogramming mechanism in tumoral endothelial cells from angiogenic to immune-permissive, interferon-responsive state through NRP1 knockdown activity
Martinsried (Munich), Germany, April 17, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that additional preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, USA, on Monday, April 20, 2026.
With our AI-empowered OligoCreator® platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.
Konstantin Petropoulos, Ph.D., MBA
CEO